From The Editors By Clive Peckar
OVER TO YOU: Eutotimes asks for your correspondence
this issue we feature an article on the work being carried out by
J. William Harbour MD and his colleagues on the development of the
HDM2 peptide, a designer compound intended to block a specific metabolic
pathway in ocular tumours which would bring about cell death.
The article is typical of the successful evolution of EuroTimes
from a publication dealing purely with anterior segment surgery
to one now covering the whole spectrum of ophthalmology.
It is our belief that we are well on the way to achieving our aim
of producing an interesting monthly news magazine which informs
our readers of what is happening in the wide world of ophthalmology.
Above all, this is your publication and while we strive to focus
our content on what we feel is the best possible response to readership
demand and interest value, we consider your suggestions and feedback
vital to our future development.
Next month sees the eighth anniversary of EuroTimes and to mark
the success of the magazine, we would like to encourage you to send
us any comments or suggestions you may have which we will then publish
in a new letters section of the magazine. Tell us what you like
and don't like and what new features, sections or commentaries you
would like to see.
We will select three outstanding contributions and award the winners
free ESCRS membership for one year. If you are already a member
you can transfer this membership to a colleague of your choice.
What is important to us is your contribution. The germ of any Society
is the collective voice of its members. That is why we encourage
each of you to use EuroTimes as a communicative platform for your
ideas and opinions.
On behalf of the editorial team, may I wish you a happy and prosperous
2003 and I look forward to hearing from you soon.
more on apoptosis, see the Bio-ophthalmology column in last month's
issue of EuroTimes.